Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)

No­var­tis' En­tresto in­fringes on uni­ver­si­ty patents, law­suit claims

More than a year and a half af­ter se­cur­ing FDA ap­proval for a block­buster heart drug, No­var­tis is now go­ing to court over it.

No­var­tis was served with a fed­er­al law­suit ear­li­er this week in the North­ern Dis­trict of Cal­i­for­nia, al­leg­ing that its heart fail­ure treat­ment En­tresto in­fringes a patent joint­ly held by the Uni­ver­si­ty of Michi­gan and the Uni­ver­si­ty of South Flori­da re­lat­ed to “en­gi­neer­ing crys­tals for the de­sign of new drug com­pounds.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.